European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2023

Barcelona, Spain 28 June 2023 - 01 July 2023

Add-on pembrolizumab ups survival in advanced HER2-negative G/GEJ cancer

10 Sep 2023 by

Adding pembrolizumab to chemotherapy significantly improved survival outcomes and response rate compared with chemo alone in patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the updated results of the KEYNOTE-859 study presented at ESMO WCGIC 2023.

Add-on pembrolizumab ups survival in advanced HER2-negative G/GEJ cancer

10 Sep 2023

HIMALAYA: Long-term OS benefit with STRIDE regimen in uHCC

07 Sep 2023 by

Treatment with tremelimumab plus durvalumab (STRIDE* regimen) continues to yield overall survival (OS) benefit at 4 years among patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib, according to the updated results of the HIMALAYA trial presented at ESMO WCGIC 2023.

HIMALAYA: Long-term OS benefit with STRIDE regimen in uHCC

07 Sep 2023

Anti-HER-2/neu vaccine may benefit gastric cancer patients

06 Sep 2023 by

In patients with HER-2-overexpressing metastatic or advanced gastric/gastroesophageal (G/GEJ) adenocarcinoma, a regimen comprising standard-of-care chemotherapy and a HER2-targeting peptide vaccine induced antibody responses that corresponded with tumour size reduction, according to an analysis of the HERIZON study which looked into the correlation between antibody responses and clinical outcomes.

Anti-HER-2/neu vaccine may benefit gastric cancer patients

06 Sep 2023

$QoL preserved in patients with refractory mCRC treated with add-on bevacizumab$

QoL preserved in patients with refractory mCRC treated with add-on bevacizumab

26 Aug 2023 by

In the treatment of refractory metastatic colorectal cancer (mCRC), the addition of bevacizumab to trifluridine/tipiracil (FTD/TPI) does not appear to hurt the quality of life (QoL), with patients receiving add-on bevacizumab being able to maintain their QoL for a longer period than those receiving FTD/TPI monotherapy, according to a post hoc analysis of the phase III SUNLIGHT trial.

QoL preserved in patients with refractory mCRC treated with add-on bevacizumab

26 Aug 2023

Intra-arterial gemcitabine bumps up survival in locally advanced pancreatic cancer

25 Aug 2023 by

In patients with locally advanced pancreatic cancer, treatment with intra-arterial gemcitabine leads to better survival and safety outcomes compared with standard-of-care therapy with intravenous gemcitabine/nab-paclitaxel, according to the first interim analysis of the phase III TIGeR-PaC trial presented at ESMO GI 2023.

Intra-arterial gemcitabine bumps up survival in locally advanced pancreatic cancer

25 Aug 2023

Topical COX inhibitor mitigates capecitabine-associated HFS in GI cancer patients

23 Aug 2023 by

Topical diclofenac gel significantly reduced the incidence of hand-foot syndrome (HFS) in patients with gastrointestinal (GI) cancer receiving capecitabine, according to findings from the exploratory subgroup analysis of the D-ToRCH* trial.

Topical COX inhibitor mitigates capecitabine-associated HFS in GI cancer patients

23 Aug 2023